CASC19通过调控miR-449b-5p影响宫颈癌细胞增殖、凋亡与辐射敏感性
该研究在宫颈癌HeLa细胞中探讨CASC19调控miR-449b-5p对增殖、凋亡和辐射敏感性的影响。随X线剂量增加CASC19表达升高而miR-449b-5p降低;沉默CASC19或过表达miR-449b-5p降低存活率与存活分数、增加凋亡,下调miR-449b-5p可部分逆转沉默CASC19的效应。双荧光素酶实验证实CASC19靶向负调控miR-449b-5p。
要点
- X线照射后HeLa细胞CASC19升高、miR-449b-5p降低。
- 沉默CASC19或过表达miR-449b-5p增强辐射敏感性并促进凋亡。
- CASC19负调控miR-449b-5p,下调后者部分逆转沉默CASC19效应。
核心结论
- HeLa细胞中CASC19可负调控miR-449b-5p的表达。
- 下调miR-449b-5p表达可部分逆转沉默CASC19对HeLa细胞增殖、凋亡及辐射敏感性的影响。
研究设计与样本
- 基础实验研究,对象为子宫颈癌细胞系HeLa细胞。
- 予不同剂量(0、2、4、6、8 Gy)X线照射,实时荧光定量PCR检测CASC19 mRNA和miR-449b-5p表达。
- 不同条件处理包括沉默CASC19、过表达miR-449b-5p、下调miR-449b-5p并沉默CASC19;MTT检测增殖,流式细胞仪检测凋亡,克隆形成实验检测辐射敏感性(存活分数)。
- 双荧光素酶报告基因实验和实时荧光定量PCR验证CASC19与miR-449b-5p靶向关系。
主要发现
- 随X线剂量(0、2、4、6、8 Gy)增加,HeLa细胞CASC19 mRNA表达逐渐升高(F=502.681,P=0.000),miR-449b-5p表达逐渐降低(F=202.936,P=0.000)。
- 沉默CASC19或过表达miR-449b-5p后,HeLa细胞存活率显著降低(P<0.05),凋亡率显著升高(P<0.05),存活分数显著降低(P<0.05),cyclin D1蛋白降低(P<0.05),cleaved-caspase-3和γ-H2AX蛋白升高(P<0.05)。
- 下调miR-449b-5p并沉默CASC19后,HeLa细胞存活率显著升高(P<0.05),凋亡率显著降低(P<0.05),存活分数显著升高(P<0.05),cyclin D1、γ-H2AX蛋白升高(P<0.05),cleaved-caspase-3降低(P<0.05)。
- 过表达miR-449b-5p可显著降低CASC19野生型荧光素酶活性(1.00±0.09 versus 0.37±0.05,P<0.01),对突变型无显著影响(0.92±0.07 versus 0.94±0.05,P>0.05)。
- 沉默CASC19后miR-449b-5p表达显著升高(1.00±0.12 versus 4.84±0.49,P<0.05),过表达CASC19后miR-449b-5p表达显著降低(1.00±0.09 versus 0.38±0.04,P<0.05)。
关键数值与推荐
- X线剂量梯度为0、2、4、6、8 Gy。
- 辐射敏感性以存活分数表示,采用细胞克隆形成实验检测。
- 双荧光素酶报告基因实验结果以荧光素酶活性表示。
临床怎么用
- 本研究为细胞水平机制探索,提示CASC19/miR-449b-5p轴可能参与宫颈癌辐射敏感性的调控。
- 结果为后续转化研究提供候选靶点,尚不能直接用于临床决策。
局限性
- 仅使用HeLa一种宫颈癌细胞系,未涉及其他细胞系或体内实验。
- 原文未报告样本量、重复次数及除上述外的统计细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the effects of cancer susceptibility candidate gene 19 (CASC19) regulating the expression of microRNA-449b-5p (miR-449b-5p) on the proliferation, apoptosis and radiation sensitivity of cervical cancer cells. Methods: (1) HeLa cells of cervical cancer cell line were cultured. HeLa cells were irradiated with X-ray at different doses (0, 2, 4, 6, 8 Gy, respectively), then the expression level of CASC19 mRNA and miR-449b-5p were detected by real-time quantitative PCR. (2) HeLa cell proliferation, apoptosis, radiation sensitivity (expressed as a survival fraction) and its related protein expression included cyclin D1, cleaved-caspase-3, and histone variant H2AX (γ-H2AX) were examined after different treatment including silencing CASC19 expression, over-expressing miR-449b-5p, down-regulating miR-449b-5p and silencing CASC19 expression. (3) The dual luciferase reporter gene experiment and real-time quantitative PCR technology were used to verify the targeting relationship between CASC19 and miR-449b-5p. Results: (1) With the increase of X-ray irradiation different dose (0, 2, 4, 6, 8 Gy), the expression level of CASC19 mRNA in HeLa cells gradually increased (F=502.681, P=0.000), and the expression level of miR-449b-5p gradually decreased (F=202.936, P=0.000).(2) After silencing CASC19 expression or over-expressing miR-449b-5p, the survival rate of HeLa cells was significantly reduced (P<0.05), the apoptosis rate was significantly increased (P<0.05), the survival fraction was significantly reduced (P<0.05), the expression level of cyclin D1 protein was significantly reduced (P<0.05), and the expression levels of cleaved-caspase-3 and γ-H2AX protein were significantly increased (P<0.05). After down-regulating miR-449b-5p and silencing CASC19 expression, the survival rate of HeLa cells was significantly reduced (P<0.05), the apoptosis rate was significantly increased (P<0.05), the survival fraction was significantly reduced (P<0.05), the expression levels of cyclin D1 and γ-H2AX protein were significantly increased (P<0.05), and the expression level of cleaved-caspase-3 was significantly decreased (P<0.05). (3) Over expression of miR-449b-5p could significantly reduce the luciferase activity of CASC19 wild type (1.00±0.09 versus 0.37±0.05, P<0.01), but there were no significant effect on the luciferase activity of CASC19 mutant type (0.92±0.07 versus 0.94±0.05, P>0.05). After the expression of CASC19 was silenced, the expression level of miR-449b-5p in HeLa cells increased significantly (1.00±0.12 versus 4.84±0.49, P<0.05). After overexpression of CASC19, the expression level of miR-449b-5p in HeLa cells was significantly reduced (1.00±0.09 versus 0.38±0.04, P<0.05). Conclusion: CASC19 in HeLa cells negatively regulates the expression of miR-449b-5p, and down-regulating the expression of miR-449b-5p could partially reverse the effects of silencing CASC19 on HeLa cell proliferation, apoptosis and radiation sensitivity. 目的: 探讨癌易感性候选基因19(CASC19)调控微小RNA-449b-5p(miR-449b-5p)的表达后对子宫颈癌细胞增殖、凋亡和辐射敏感性的影响。 方法: (1)培养子宫颈癌细胞系HeLa细胞,予不同剂量(分别为0、2、4、6、8 Gy)的X线照射,实时荧光定量PCR技术检测HeLa细胞中CASC19 mRNA和miR-449b-5p的表达水平。(2)不同条件处理后HeLa细胞增殖、凋亡、辐射敏感性及其相关蛋白表达的检测,其中,不同处理条件包括沉默CASC19表达、过度表达miR-449b-5p、下调miR-449b-5p并沉默CASC19表达,相关蛋白包括细胞周期蛋白D1(cyclin D1)、活化的半胱氨酸天冬氨酸蛋白酶3(cleaved-caspase-3)和组蛋白变异体H2AX(γ-H2AX);采用四甲基偶氮唑蓝(MTT)比色法检测细胞增殖情况,流式细胞仪检测细胞凋亡情况,细胞克隆形成实验检测细胞的辐射敏感性(以存活分数表示)。(3)采用双荧光素酶报告基因实验(结果以荧光素酶活性表示)和实时荧光定量PCR技术验证CASC19和miR-449b-5p之间的靶向调控关系。 结果: (1)随着X线照射剂量(0、2、4、6、8 Gy)的增加,HeLa细胞中CASC19 mRNA的表达水平逐渐升高(F=502.681,P=0.000),miR-449b-5p的表达水平逐渐降低(F=202.936,P=0.000)。(2)沉默CASC19表达、过度表达miR-449b-5p后,HeLa细胞的存活率显著降低(P<0.05),凋亡率显著升高(P<0.05),存活分数显著降低(P<0.05),cyclin D1蛋白的表达水平显著降低(P<0.05),cleaved-caspase-3和γ-H2AX蛋白的表达水平显著升高(P<0.05);下调miR-449b-5p并沉默CASC19表达后,HeLa细胞的存活率显著升高(P<0.05),凋亡率显著降低(P<0.05),存活分数显著升高(P<0.05),cyclin D1、γ-H2AX蛋白的表达水平显著升高(P<0.05),cleaved-caspase-3的表达水平显著降低(P<0.05)。(3)与对照比较,过度表达miR-449b-5p可显著降低CASC19基因野生型HeLa细胞的荧光素酶活性(分别为1.00±0.09、0.37±0.05,P<0.01),而对CASC19基因突变型HeLa细胞的荧光素酶活性无显著影响(分别为0.92±0.07、0.94±0.05,P>0.05)。与对照比较,沉默CASC19表达后HeLa细胞中miR-449b-5p的表达水平显著升高(分别为1.00±0.12、4.84±0.49,P<0.05),过度表达CASC19后HeLa细胞中miR-449b-5p的表达水平显著降低(分别为1.00±0.09、0.38±0.04,P<0.05)。 结论: HeLa细胞中CASC19可负调控miR-449b-5p的表达,下调miR-449b-5p表达可部分逆转沉默CASC19对HeLa细胞增殖、凋亡及辐射敏感性的影响。.
引用
- Liu YJ, Guo RX, Han LP, et al. [Effect of CASC19 on proliferation, apoptosis and radiation sensitivity of cervical cancer cells by regulating miR-449b-5p expression]. Zhonghua Fu Chan Ke Za Zhi. 2020. PMID: 32074771. doi:10.3760/cma.j.issn.0529-567X.2020.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。